Monopar Therapeutics (MNPR) Q2 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.62

Estimate

-$0.65

Surprise

+4.5%

Score today

5.2/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Monopar Therapeutics (MNPR) reported a narrower loss than forecast — adjusted EPS of -$0.62 against the -$0.65 estimate (a 4.5% beat on a still-unprofitable quarter).

• This Stubhub Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday — benzinga, 2026-08-13
• Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $128 — benzinga, 2026-08-13
• Cantor Fitzgerald Downgrades Monopar Therapeutics to Neutral, Raises Price Target to $119 — benzinga, 2026-08-13

TrendMatrix currently rates MNPR Sell at 5.2/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's +4.5% surprise compares with a +3.5% four-quarter average. Next scheduled report: 2026-11-12.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$71.50

Price target

$113.03

Stop

$66.75

Upside to target

+58.1%

Reward-to-risk

5.9:1

Model outputs from TrendMatrix’s engine as of 2026-10-27 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$473.5M

P/E (fwd)

-36.8

52-week range

$50.07–$124.82

Off 52-week high

42.7%

RSI (14)

27

Volume vs avg

0.22×

Score today

5.2/10